138 related articles for article (PubMed ID: 25144286)
21. Surgery plus adjuvant radiotherapy for primary central nervous system lymphoma.
Kinslow CJ; Rae AI; Neugut AI; Adams CM; Cheng SK; Sheth SA; McKhann GM; Sisti MB; Bruce JN; Iwamoto FM; Sonabend AM; Wang TJC
Br J Neurosurg; 2020 Dec; 34(6):690-696. PubMed ID: 31931632
[No Abstract] [Full Text] [Related]
22. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.
Roth P; Martus P; Kiewe P; Möhle R; Klasen H; Rauch M; Röth A; Kaun S; Thiel E; Korfel A; Weller M
Neurology; 2012 Aug; 79(9):890-6. PubMed ID: 22895585
[TBL] [Abstract][Full Text] [Related]
23. Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases.
Bellinzona M; Roser F; Ostertag H; Gaab RM; Saini M
Eur J Surg Oncol; 2005 Feb; 31(1):100-5. PubMed ID: 15642434
[TBL] [Abstract][Full Text] [Related]
24. [Primary CNS lymphoma--an update].
Soussain C; Houillier C; Choquet S; Hoang-Xuan K
Bull Cancer; 2014 Mar; 101(3):314-24. PubMed ID: 24691194
[TBL] [Abstract][Full Text] [Related]
25. Primary central nervous system lymphoma in Japan: changes in clinical features, treatment, and prognosis during 1985-2004.
Shibamoto Y; Ogino H; Suzuki G; Takemoto M; Araki N; Isobe K; Tsuchida E; Nakamura K; Kenjo M; Suzuki K; Hosono M; Tokumaru S; Ishihara S; Kato E; Ii N; Hayabuchi N
Neuro Oncol; 2008 Aug; 10(4):560-8. PubMed ID: 18559969
[TBL] [Abstract][Full Text] [Related]
26. Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s.
Shibamoto Y; Ogino H; Hasegawa M; Suzuki K; Nishio M; Fujii T; Kato E; Ishihara S; Sougawa M; Kenjo M; Kawamura T; Hayabuchi N
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):809-13. PubMed ID: 15936564
[TBL] [Abstract][Full Text] [Related]
27. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.
Poortmans PM; Kluin-Nelemans HC; Haaxma-Reiche H; Van't Veer M; Hansen M; Soubeyran P; Taphoorn M; Thomas J; Van den Bent M; Fickers M; Van Imhoff G; Rozewicz C; Teodorovic I; van Glabbeke M;
J Clin Oncol; 2003 Dec; 21(24):4483-8. PubMed ID: 14597741
[TBL] [Abstract][Full Text] [Related]
28. Unusual variants of primary central nervous system lymphoma.
Shenkier TN
Hematol Oncol Clin North Am; 2005 Aug; 19(4):651-64, vi. PubMed ID: 16083828
[TBL] [Abstract][Full Text] [Related]
29. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
30. Fluorescein sodium-guided surgery in cerebral lymphoma.
Schebesch KM; Hoehne J; Hohenberger C; Acerbi F; Broggi M; Proescholdt M; Wendl C; Riemenschneider MJ; Brawanski A
Clin Neurol Neurosurg; 2015 Dec; 139():125-8. PubMed ID: 26432995
[TBL] [Abstract][Full Text] [Related]
31. Primary central nervous system lymphoma: a profile of 26 cases from Western India.
Agarwal PA; Menon S; Smruti BK; Singhal BS
Neurol India; 2009; 57(6):756-63. PubMed ID: 20139505
[TBL] [Abstract][Full Text] [Related]
32. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
[TBL] [Abstract][Full Text] [Related]
33. Surgery for primary CNS lymphoma? Challenging a paradigm.
Weller M; Martus P; Roth P; Thiel E; Korfel A;
Neuro Oncol; 2012 Dec; 14(12):1481-4. PubMed ID: 22984018
[TBL] [Abstract][Full Text] [Related]
34. Expression of cyclooxygenase-2 and vascular endothelial growth factor in primary central nervous system lymphomas.
Sugita Y; Komatani H; Ohshima K; Shigemori M; Nakashima A
Oncol Rep; 2007 Sep; 18(3):617-22. PubMed ID: 17671709
[TBL] [Abstract][Full Text] [Related]
35. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment.
Hormigo A; Abrey L; Heinemann MH; DeAngelis LM
Br J Haematol; 2004 Jul; 126(2):202-8. PubMed ID: 15238140
[TBL] [Abstract][Full Text] [Related]
36. Primary central nervous system lymphoma.
Abrey LE
Curr Opin Neurol; 2009 Dec; 22(6):675-80. PubMed ID: 19741527
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of clinical characteristics and immunophenotypic biomarkers in 115 patients with primary central nervous system lymphoma.
Chen BB; Xu XP; Shen L; Han TJ; Lin ZG; Chen Z; Kang H; Huang B; Lin GW
Chin Med J (Engl); 2013 Feb; 126(3):482-7. PubMed ID: 23422111
[TBL] [Abstract][Full Text] [Related]
38. Primary central nervous system lymphomas: a 30-year experience at a single institution.
Nuckols JD; Liu K; Burchette JL; McLendon RE; Traweek ST
Mod Pathol; 1999 Dec; 12(12):1167-73. PubMed ID: 10619271
[TBL] [Abstract][Full Text] [Related]
39. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma.
Braaten KM; Betensky RA; de Leval L; Okada Y; Hochberg FH; Louis DN; Harris NL; Batchelor TT
Clin Cancer Res; 2003 Mar; 9(3):1063-9. PubMed ID: 12631608
[TBL] [Abstract][Full Text] [Related]
40. Diagnostics and treatment delay in primary central nervous system lymphoma: What the neurosurgeon should know.
Hasner MC; van Opijnen MP; van der Meulen M; Verdijk RM; Maas SLN; Te Boome LCJ; Broekman MLD
Acta Neurochir (Wien); 2024 Jun; 166(1):261. PubMed ID: 38858236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
